Review Article

Particles in Progress: Unveiling the Emerging Influence of Nanoplastics on Parkinson's Pathology and Neurodegeneration

Mr. Alin Bose Johnson[1*], Ms Niharika Modi[2], Dr Raman Rajesh Kumar[3], Dr Vasanth Raj Palanimuthu[4]

[1,2,3,4]Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.

Abstract

This review delves into the intricate interplay between nanoplastics and Parkinson's disease (PD), exploring the emerging evidence surrounding the potential role of these minuscule plastic particles in the pathogenesis of the neurodegenerative disorder. Nanoplastics, defined as particles ranging from 1 to 100 nanometers, are a byproduct of the breakdown of larger plastic materials and have garnered attention due to their ability to traverse biological barriers, including the blood-brain barrier. The intricate mechanisms by which nanoplastics may contribute to PD pathology involve direct interactions with neuronal cells and the facilitation of alpha-synuclein aggregation. Strategies to curtail nanoplastics' environmental presence, such as enhanced waste management and the promotion of biodegradable materials, could mitigate the risk of PD development. The potential disruption of the interaction between nano plastics and alpha-synuclein suggests that future therapies targeting this process could be instrumental in managing PD and impeding the spread of its pathological manifestations within the brain's neural networks. This comprehensive exploration of the nexus between nanoplastics and PD underscores the significance of understanding and addressing the environmental factors contributing to neurodegenerative diseases.

Keywords: Nanoparticles , Parkinson’s disease , Alpha-synuclein, Aggregates , Lewy bodies.

Introduction:

In recent years, the field of nanotechnology has witnessed exponential growth in multiple scientific disciplines. One intriguing advancement that has emerged is the development of nanoplastics, tiny fragments of plastic measuring less than 100 nm in size. While the impact of plastic pollution on the environment and marine life has been well-documented, the emerging role of nanoplastics in human health is only starting to be unraveled. This article aims to explore the potential association between nanoplastics and Parkinson's disease, shedding light on recent scientific findings and discussing the implications of this emerging field.

*Corresponding author
Email address: alinbose@jssuni.edu.in (Alin Bose Johnson)
Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.

Nanoplastics and the Human Body:

Accumulating evidence suggests that nanoplastics have the potential to penetrate various biological barriers, including cell membranes, blood-brain barriers, and cellular organelles. Their size allows them to be taken up by cells, where they may elicit a range of toxic effects. Once inside the body, nanoplastics can become lodged in tissues, interact with cellular components, and induce oxidative stress, inflammation, and cellular dysfunction. These adverse effects have raised concerns about their possible connection to neurodegenerative diseases such as Parkinson's disease.

Parkinson's Disease: An Overview:

Parkinson's disease is a complex and progressive neurological disorder that affects the central nervous system. It is characterized by the degeneration of dopaminergic neurons in a region of the brain called the substantia nigra, leading to a variety of motor and non-motor symptoms. While the precise cause of Parkinson's disease remains unknown, it is widely believed to involve a combination of genetic predisposition and exposure to environmental factors.



The Impact of Nanoplastics on Parkinson's Disease:

Emerging studies have begun investigating the potential role of nanoplastics in Parkinson's disease. Researchers have found a link between exposure to certain types of nanoplastics and the acceleration or exacerbation of neurodegenerative processes. One key mechanism proposed is the generation of reactive oxygen species (ROS) through the interaction of nanoplastics with neurons, leading to oxidative stress and the eventual death of dopaminergic neurons. Additionally, nanoplastics have been shown to induce inflammation, disrupt cellular homeostasis, and impair mitochondrial function, all of which are key hallmarks of Parkinson's disease pathology. Importantly, the potential association between nanoplastics and Parkinson's disease is not limited to inhalation or direct exposure

to commercial nanoplastic materials. The breakdown of larger plastic debris into nanoplastics in the environment further raises concerns about oral ingestion, as everyday foods and drinking water may contain nanoplastics. Consequently, chronic exposure to nanoplastics through various routes of intake may play a significant role in the development or progression of Parkinson's disease.

The Emerging Role of Nanoplastics in Parkinson's Disease Introduction Parkinson's disease (PD) is a neurodegenerative disorder that affects millions of people worldwide. It is characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor impairments, cognitive decline, and other debilitating symptoms. While the exact cause of PD remains unknown, emerging evidence suggests that environmental factors, such as exposure to certain toxins, may play a significant role in disease development. In recent years, attention has been drawn to the potential role of nanoplastics, tiny particles derived from the breakdown of plastic waste, in Parkinson's disease pathology. Nanoplastics and Parkinson's Disease Nanoplastics are defined as plastic particles with a size range of 1-100 nanometers. These particles are formed through the fragmentation and degradation of larger plastic objects, such as water bottles, food containers, and packaging materials. Due to their small size and ability to penetrate various biological barriers, nanoplastics have raised concerns regarding their potential toxicity and impact on human health. In recent studies, researchers have started to investigate the link between nanoplastics and PD, as the brain is highly susceptible to the accumulation of foreign particles. The exact mechanisms through which nanoplastics contribute to PD pathology are not yet fully understood. However, several proposed pathways warrant further investigation. One possible mechanism is the direct interaction of nanoplastics with neuronal cells. Studies have shown that nanoplastics can penetrate the blood-brain barrier and accumulate in brain regions affected by PD pathology, such as the substantia nigra. Once inside the brain, nanoplastics may trigger neuroinflammation and oxidative stress, leading to the degeneration of dopaminergic neurons.

Another potential mechanism involves the interaction of nanoplastics with alpha-synuclein, a protein that forms proteinaceous aggregates (Lewy bodies) in PD. Research has demonstrated that nanoplastics can adsorb and transport alpha-synuclein, facilitating its aggregation and propagation within the brain. This process may contribute to the spread of PD pathology through the brain's interconnected neural networks. Implications for Disease Prevention and Treatment Understanding the role of nanoplastics in PD opens up new avenues for disease prevention and treatment.

Firstly, efforts should focus on reducing the production and release of nanoplastics into the environment. This can be achieved through stricter regulations on plastic waste management, promoting the use of biodegradable materials, and raising awareness among individuals about the environmental impact of plastic consumption. Additionally, innovative therapeutic strategies may emerge from targeting nanoplastics in PD. One potential approach involves the development of nanomaterials capable of neutralizing or clearing nanoplastics from the brain.

By removing these toxic particles, the progression of PD pathology could be slowed or halted. Furthermore, nanoplastics' role in facilitating the spread of alpha-synuclein aggregates suggests that therapies targeting this process could be effective. Developing drugs or nanotherapeutics that block the interaction between nanoplastics and alpha-synuclein could prevent the propagation of PD pathology and enhance disease management. Conclusion In conclusion, the emerging research on the role of nanoplastics in Parkinson's disease highlights a potential link between plastic pollution and neurodegenerative disorders. While further studies are needed to elucidate the precise mechanisms and effects of nanoplastics in PD, the current evidence suggests that these tiny plastic particles may contribute to disease development and progression. Efforts should focus on reducing the release of nanoplastics into the environment, developing strategies to remove or neutralize them from the brain, and targeting their interaction with alpha-synuclein for potential therapeutic interventions.

Conclusion:

Although the precise relationship between nano plastics and Parkinson's disease requires further investigation, the emerging evidence highlights a potential connection between the two. The ability of nanoplastics to cross biological barriers and elicit toxic effects on cellular components supports the hypothesis that exposure to these particles may contribute to the development or exacerbation of Parkinson's disease. As the detrimental impact of plastic pollution on the environment continues to be a pressing concern, understanding the potential health risks of nanoplastics is crucial. Consequently, further research into this emerging field is essential in order to develop effective preventive and therapeutic strategies to combat Parkinson's disease. By understanding and addressing the emerging role of nanoplastics in PD, we can take significant steps towards mitigating the burden of this devastating disease.

References

1. Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med. 2009;11:e22.
2. 2. Bove J, Perier C. Neurotoxin-based models of Parkinson's disease. Neuroscience. 2012;211:51-76.
3. Wright SD, Ramos KS. The influence of the environment on neurodegeneration and neuroinflammation.Toxicol Pathol. 2013;41:525-47.
4. Koelmel JP, Krois D, Wiktorowicz JE, et al.Plastic waste as a novel substrate for PET depolymerization and upcycling. Chemsuschem.2020;13:3119-3127.
5. Li D, Zou L, Li M, et al. The effect of nanoplastic on neurotransmitter secretion from mice posterior pituitary.Chemosphere. 2020;244:125431.

6. 6. Lee JJ, Koparde VN, Koprivica N, et al.Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours. Nat Biomed Eng.2018;2:497-507.
7. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012;14:1-16.
8. Breger JC, Chaves-Moreno D, Guzman-Villanueva D, et al.Interactions between nanoparticles and proteins: from corona composition to biodistribution. Nanomedicine. 2020;15:2021-2032.
9. Dehay B, Bourdenx M, Gorry P, et al. Targeting alpha-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol. 2015;14:855-866.
10. 10. Melamed E, Ziv I, Djaldetti R.From the past to the future: the new form of drug delivery for Parkinson's disease. Parkinsonism Relat Disord. 2009;15 Suppl 3:S105-107..